Opinion: Mifepristone court ruling makes drug development riskier for everyone

The 5th Circuit’s ruling on mifepristone “is bad for health care access, and it’s also bad for innovation,” writes Grace E. Colón.

More from STAT

Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies

STAT·3

Pump the brakes on AI, buddy; and deposition deadlock

STAT·7

UCB to acquire maker of antibody treatments for autoimmune diseases

STAT·8

What to know about hantavirus, the illness suspected in a cruise ship outbreak

STAT·7

STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news

STAT·4

Federal court blocks mailing of mifepristone

STAT·5